1. Home
  2. CFND vs IVVD Comparison

CFND vs IVVD Comparison

Compare CFND & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$4.00

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.70

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
IVVD
Founded
N/A
2020
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
437.1M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CFND
IVVD
Price
$4.00
$1.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.75
AVG Volume (30 Days)
23.1K
1.7M
Earning Date
N/A
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
N/A
$143.48
Revenue Next Year
N/A
$25.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
110.47
52 Week Low
$3.68
$0.46
52 Week High
$9.67
$3.07

Technical Indicators

Market Signals
Indicator
CFND
IVVD
Relative Strength Index (RSI) 45.83 46.09
Support Level $3.75 $1.41
Resistance Level $4.08 $1.77
Average True Range (ATR) 0.19 0.12
MACD 0.04 0.02
Stochastic Oscillator 54.00 32.93

Price Performance

Historical Comparison
CFND
IVVD

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: